IL-l !3 and IL-6 has been observed in CSF of acute stroke patients; in the same study IL-6 serum levels appeared increased up to 90 days after stroke (Tarkowski et al., 1995) . However, data on peripheral cytokines after stroke are still controversial. In one study (Fassbender et al., 1994) IL-6 serum levels increased within the first hours after stroke, reached a plateau at 10 hours, and returned to baseline by day 7. No change in IL-1!3 and TNF-a level was observed in the same study. In another study (Beamer et al., 1995) plasma levels of IL-6 and IL-1 receptor antagonist were found to be increased at 4±2 days after stroke. In a more recent study , IL-6 serum concentration was reported to be in creased up to day 7. In some but not all studies, TNF-a serum levels or soluble TNF receptor protein-1 p55 ap peared increased after stroke (DeGraba et al., 1996; EI neihoum et al., 1996; Intiso et al., 1997) .
Discrepancies of these results might be due to the short half-life of cytokines, to possible high concentra tions at the site of release and much lower concentrations after their dilution in blood and to the different types of assay because bioassays measure biological activity of intact cytokines, while immunological assays also mea sure cytokine fragments or monomers without biological activity.
Moreover, in view of the existance of communication pathways linking the brain to the periphery (De , measuring circulating cytokines (in CSF and se rum) does not definitely establish their source (central or peripheral) after stroke. To get a deeper insight into the pathogenetic role of cytokines in this condition we wished to determine the source and the time course of peripheral cytokines and to relate them to the type of stroke and to measures of severity and outcome. We obtained blood cells from acute stroke patients (includ ing both ischemic and hemorragic) at various times (from the first day up to 3 months) and investigated IL-6 and TNF-a production after in vitro exposure to lipo polysaccharide (LPS) (ex vivo). Circulating serum cyto kines were also investigated at the same time points and all values were correlated with brain lesion size, with stroke severity and outcome, and with peripheral inflam matory indexes.
SUBJECTS AND METHODS

Patients and controls
We enrolled 55 patients with acute stroke (within 24 hours after the onset) who were admitted to the Department of Neu rology of the University of Milan at the San Gerardo Hospital, in Monza, Italy, from January 1996 through December 1997. The study was approved by the Ethic Committee of San Gerardo Hospital. Excluded from the study were patients with history of recent (within 3 months before admission) infection, concurrent major cardiac, renal, hepatic, autoimmune and can cerous diseases, recent (within I year) history of prior transient ischemic attacks, stroke or head trauma, and signs of acquired infection after admission. Patients taking immunosuppressive or anti-inflammatory drugs were also excluded. Ticlopidine or heparin were admitted for secondary stroke prevention. In pre liminary experiments, we tested these drugs and found them not active on cytokine release or cytokine assays (data not shown).
All patients underwent complete physical and neurologic ex amination at entry and stroke severity was assessed by the National Institutes of Health Stroke Scale (Brott et aI., 1989) at the onset of stroke and then at days 2, 4, 10, 30, and 90 after stroke. All patients were examined with computerized tomog raphy of the brain within 24 hours and at 5 days after stroke. The volume of ischemia or hemorrhage was determined from standard computed tomography scans by calculating the vol ume of an ellipsoid containing the lesion (Pullicino et aI., 1997) and also using the "Cavalieri Direct Estimator," as previously described (Clatterbuck et aI., 1997) . Both measurements were corrected to in vivo dimensions using the analog scale found on the hard copy computed tomography image, had good interrater agreement and were highly correlated to each other (r = 0.99, P < .0001). Blood cell count, including monocytes and plate lets, and analysis of erythrocyte sedimentation rate, C-reactive protein, fibrinogen, protein C and S, antiphospholipid antibod ies were performed in all patients at entry and at 10 days after stroke.
Twenty healthy control subjects, without known stroke risk factors (blood donors of the San Gerardo Hospital), balanced for age with the stroke group, were also selected for analysis of cytokine release. Demographic and clinical characteristics of patients and controls are shown in Table I . Because nine pa tients were lost for intercurrent infections and six patients died, 40 of 55 (73%) completed the study. Among the studied pa tients, 29 had ischemic and II had hemorragic brain lesions; their data were analyzed both together and as separate groups.
For cytokine measurements studies, patients' blood was se rially drawn, after informed consent, through the antecubital vein within 48 hours and at days 4, 10, 30, and 90 from stroke onset. Seven milliliters were immediately used for blood cell stimulation studies, 3 mL of serum were also stored for analysis of cytokine levels.
Blood samples from controls were collected with a similar procedure at only one time point because preliminary experi ments have shown that in healthy subjects cytokine release remains stable during serial venipuncture.
Whole blood stimulation
Experiments were performed as described by Fantuzzi et al. (1995) with minor modifications. Heparinized whole blood ob tained from stroke patients and healthy controls was immedi ately processed. Blood was diluted 1:2 (v/v) in RPMI 1640 medium (without bovine serum), plated in 96-well tissue cul ture plates (200Il-Liwell), and incubated for 4 hours at 37°C and 5% CO2, in the presence of 0.01 nmol/L endotoxin (Il-LPS: phenol-extracted preparation from Escherichia coli 055: B5 [Sigma] dissolved in sterile pyrogen-free saline) or the same volume of pyrogen-free saline. After incubation, whole blood was centrifuged and supernatants collected and stored at -20°C until assay.
Cytokine assays
For each patient, assays were performed when sample col lection had been completed (day 90 from stroke). Eight patients and four controls were processed in the same assay and samples were run in triplicate. Interleukin-6 bioassay. IL-6 was measured in cell superna tant as hybridoma growth factor using the 7TDI cell line as previously described (De Simoni et a!., 1990) . Results are ex pressed as units per milliliter in comparison with a reference curve obtained in each experiment using recombinant human IL-6 (Immunex, Seattle, W A). Reference curves obtained were comparable in all experiments. One unit in the 7TDI assay corresponded to I pg human recombinant IL-6. The sensitivity of the assay was 50 U/mL. TNF-rx bioassay. TNF-rx was measured in cell supernatant by cytotoxicity on L929 cells in the presence of 0.001 j.LmollL of actinomycin D as previously described (Terrazzino et a!., 1997) . TNF-rx levels were calculated using recombinant human TNF-rx (BASF/Knoll, Ludwigshafen, Germany; specific activ ity 107 U/mg) and expressed as nanograms per milliliter. The sensitivity of the bioassay was 5 pg/mL. IL-6 and TNF-rx immunoassays. For the quantitative mea surement of IL-6 and TNF-rx in serum we used both the bio assay and the Immulite Automated Immunoassay System (DPC, Cirrus, New Jersey, USA). With this method, a poly styrene bead solid phase (Immulite Test Unit) is coated with a monoclonal antibody specific for human TNF-rx or IL-6, with no cross-reactivity to other cytokines. Sensitivity of the assay was 1.7 pg/mL for TNF-rx and I pg/mL for IL-6.
Statistical analysis
The significance of cytokine production in patients com pared to controls was analyzed by one-way analysis of variance (Dunnett' s test). Difference between ischemic and hemorragic patient samples at single time points was evaluated by Stu dent' s t-test.
Statistic ahalysis of correlations between cytokine values and brain lesion volume, stroke severity, outcome and peripheral inflammatory indexes was performed with the Pearson' s cor relation test. Figure 1 shows the time course of IL-6 release from blood cells of stroke patients. After stimulation, the re lease was significantly higher than that from controls' cells at all time points from days 1 to 2 after stroke until 1 month, and it was still 127% of controls after 3 months, although no longer statistically different. The highest re- lease was observed at day 4 after stroke (224%, P < .01 versus controls), but at 30 days it was still about 160% of the controls. IL-6 was not detectable when blood cells were not exposed to LPS. TNF-a release, shown in Fig. 2 , was significantly in creased from days 1 to 2 up to 3 months after stroke. There was no peak response, the mean increase being about three-fold compared to controls from days 1 to 2 through day 30. At 3 months TNF-a values were still 226% of controls. As for IL-6, TNF-a was not detectable in nonstimulated supernatants.
RESULTS
When ischemic and hemorragic strokes were analyzed separately, a difference in the time-course of IL-6 release became evident (Fig. 3) . In fact, IL-6 increased earlier in ischemic compared to hemorragic patients, the difference being evident at days 1 to 2 and 4, and disappearing from day lO. Thus, the peak response appeared at day 4 in the ischemic and at day 10 in the hemorragic stroke. No difference could be shown in the time-course of TNF-rx release in the two patient groups (data not shown).
Analysis of possible correlations between the increase of cytokine release and stroke severity at the onset (ex pressed by the National Institutes of Health Stroke Scale score), residual damage (expressed by National Institutes of Health Stroke Scale score at 3 months) or clinical improvement (measured as a difference of the two scores) did not reveal any significant correlation (data not shown). Moreover, no relation between cytokine in crease and the volume of ischemic or hemorragic lesion was observed (data not shown).
Finally, cytokine release was neither related to periph eral indeces of inflammation such as erythrocyte sedi mentation rate, C-reactive protein, fibrinogen, nor to the number of leukocytes or monocytes. Antiphospholipid antibodies have been observed in one hemorragic and three ischemic patients; the increase in cytokine release in these patients was similar to that of other patients.
Analysis of serum levels of circulating cytokines by bioassays did not show detectable levels neither in con trols nor in stroke patients. On the contrary, immuno logical analysis by Immulite showed increased concen trations of IL-6 at all time points, with peaks at 4 and lO days ( Table 2) . TNF-a serum levels were only slightly and not significantly increased at day 1 to 2, and were similar to controls at later times. No correlation has been found between the release from blood cells measured by bioassay and serum levels of cytokines measured by im munological assay (data not shown). Serum cytokine lev els were also unrelated to stroke size and severity (data not shown).
DISCUSSION
In this article we show for the first time that blood cells from patients with acute stroke (ex vivo) release larger amounts of IL-6 and TNF-a after exposure to LPS, a trigger of cytokine production.
This finding may answer some questions and meth odologic problems recently raised in the literature. Our results suggest that activated peripheral blood cells should be a major source of cytokines described in vari ous studies (Fassbender et aI., 1994; Beamer et aI., 1995; Kim et aI., 1996; Intiso et aI., 1997; Elneihoum et aI., 1996; DeGraba et aI., 1996) in plasma or serum of stroke patients; accordingly, cytokine leakage from infarcted brain or from CSF should not represent the main con tributor to circulating cytokines. This is in line with a previous study showing no correlation between CSF and serum cytokine levels early after stroke, when they are higher in CSF than in serum (Tarkowski et aI., 1995) ; in the same study the correlation appeared only from day 21 to day 90 after stroke, when their gradient indicated a blood to CSF flow (Tarkowski et aI., 1995) . Our data of protracted release of cytokines from peripheral blood cells favors this interpretation.
Moreover, we observed increased serum IL-6 levels by immunological assay, but not by bioassay, that yielded undetectable concentration for both cytokines. For IL-6, but not for TNFa, this could be due to the different sensitivity of the assays, the immunoassay be ing more sensitive than the 7TDI bioassay. The different results obtained with the two assays could also indicate that most of the immunomaterial detected in serum is related to cytokine fragments or monomers without bio logical activity (Turtinen and Juran, 1998) , and that re lease studies are more reliable than serum measurements. The normal number of leukocytes and in particular of monocytes (the major source of blood cytokines) and the lack of correlation between monocyte counts and cyto kine release indicate that the increased release is linked to blood cell activation and not to monocytosis.
After clearing these methodologic issues, we like to discuss the physiopathologic and clinical relevance of our finding. First of all, we observed that IL-6 release is activated in ischemic and hemorragic strokes with a dif ferent pattern. Thus, the different brain tissue reactions may play a specific role in the activation of peripheral blood cells. This is in line with the different expression of cytokine mRNA observed in brain tissue from patients who died at various times after cerebral ischemia or hem orrhage (Tomimoto et aI., 1996) . These observations in dicate that specific brain modifications after stroke trig ger peripheral immunologic activation.
The mechanism whereby a CNS lesion such as brain ischemia or hemorrhage activates peripheral blood cells is still unclear, although the existance of a signaling path way from the brain to the periphery has been clearly shown (De Simoni et aI., 1990; . Ex perimental data show that an inflammatory stimulus (such as IL-l or endotoxin) delivered in the brain effi ciently induces inflammatory cytokine production in the periphery (De Simoni et aI., 1993; . The present data indicate that a peripheral immune response is elic ited by stroke and further underlines the brain-immune system communication pathway in this type of CNS le sion. Because we did not find a correlation between the lesion volume or stroke severity and cytokine release, it is possible that even small lesions may activate periph eral immune system. On the other hand, it has been repeatedly shown that peripheral cytokines may affect CNS by several mecha nisms (De . Moreover, leukocytes and monocytes recruited from the periphery have been shown in brain infarcts (Kochanek and Hallenbeck, 1992; Wang et aI., 1993) , and a direct passage of cyto kines from peripheral blood to CNS has been proposed (Banks et aI., 1994; Gutierrez et aI., 1993) . Thus, the possibility that peripherally produced cytokines may in turn affect the brain should also be considered.
The role of cytokines in stroke is intriguing and it is difficult to establish a role of each individual inflamma tory cytokine in the pathogenesis of the ischemic pro cess, given their diverse functions and the multiplicity of various cytokine activation. Several experimental studies suggest a role for IL-6 and TNF-a in the pathogenesis of CNS diseases and in neuronal damage, possible mecha nisms being the inhibition of glutamate uptake and the facilitation of excitotoxicity (Ye and Sontheimer, 1996; Fine et aI., 1996) . On the other hand, both cytokines display also protective actions in the brain (Bruce et aI., 1996) and possess neurotrophic activity in vitro, an effect which may be direct and/or mediated by neurotrophic factors (Hama et aI., 1989; Gadient et aI., 1990; Yamada and Hatanaka, 1 994; Kossmann et aI., 1996) .
In line wi�h these neurotrophic activities, our demon stration of a protracted activation of blood cells after acute stroke raises the possibility that cytokines released from these cells are involved not only in the mechanisms of acute reaction to brain infarct, but also in the mecha nisms of plasticity and repair. Recently, the importance of cytokines and growth factors as signaling mechanisms not only in stroke recovery, but also as protection from further insults (ischemic tolerance or preconditioning) has been underscored (Chen and Simon, 1997; Hallen beck, 1997; Mattson, 1997) .
We have interpreted the increase in TNF-a levels ob served throughout the study as a consequence of the stroke event; however, data in the literature suggest that an alternative explanation should also be considered. Ex perimental data show that genetically stroke prone/ hypertensive rats produce more TNF-a in response to a provocative dose of LPS intravenous than control ani mals free of these risk factors (Hallenbeck et aI., 1991) . Thus, high TNF-a levels in stroke patients could be the result of a greater susceptibility of blood cells to inflam matory stimuli present before the stroke event. The data open the possibility that genetic differences and/or stroke risk factors may contribute to the marked and long lasting TNF-a production observed. Persistent inflam matory response has been recently shown in stroke sur vivors, associated with increased risk for recurrent vas cular events (Beamer et aI., 1998) .
Finally, our findings show the possibility to analyze the peripheral immunologic activation in patients with J Cereb Blood Flow Metah. Vol. 19, No.9, 1999 brain lesions such as stroke, with the aim of investigating their involvement in the mechanisms of stroke damage and repair.
